Monoclonal Antibody Therapeutics Market Analysis | CMI - PowerPoint PPT Presentation

View by Category
About This Presentation

Monoclonal Antibody Therapeutics Market Analysis | CMI


Read here the latest updates on the Monoclonal Antibody Therapeutics Market Analysis published by CMI team – PowerPoint PPT presentation

Number of Views:1
Date added: 15 September 2020
Slides: 12
Provided by: Shweta2707
Category: Other


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Monoclonal Antibody Therapeutics Market Analysis | CMI

  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//
  • COVID-19 Impact Tracker

  • Monoclonal Antibody Therapeutics Market, by
    Source (Human, Humanized, Chimeric, and Others),
    by Therapeutic Application (Oncology, Autoimmune
    Diseases, Infectious Diseases, Hematological
    Disorders, and Others), by Distribution Channel
    (Hospital Pharmacies, Retail Pharmacies, Online
    Pharmacies, and Specialty Pharmacies), and by
    Region (North America, Latin America, Europe,
    Asia Pacific, the Middle East, and Africa) -
    Size, Share, Outlook, and Opportunity Analysis,
  • The global monoclonal antibody therapeutics
    market was valued at US 95,560.5 million in
    2017, and is expected to witness a robust CAGR of
    6.9 over the forecast period (20182026).

Market Drivers
  • Increasing drug approvals and launch of novel
    monoclonal antibodies for treatment of various
    diseases such as cancer are expected to boost the
    market growth over the forecast period
  • Frequent approvals of novel monoclonal antibodies
    and their launches in developed economies are
    expected to significantly drive Monoclonal
    Antibody Therapeutics Market growth over the
    forecast period. Key players in the market have
    gained regulatory approvals and have launched
    their therapies in the market. For instance, in
    2015, the U.S. FDA approved Darzalex, developed
    by Johnson Johnson for multiple myeloma.
    Similarly, in 2017, Roche was granted accelerated
    approval to TECENTRIQ (atezolizumab) from the U.S
    FDA for the treatment of people with locally
    advanced or metastatic urothelial carcinoma (mUC)
    who are not eligible for cisplatin chemotherapy.
  • Moreover, approvals to several combination
    therapies are further expected to boost the
    global monoclonal antibody therapeutics market
    growth over the forecast period. For instance, in
    2017, the U.S. FDA approved Darzalex
    (daratumumab) in combination with pomalidomide
    and dexamethasone for the treatment of patients
    suffering from multiple myeloma. Moreover,
    different monoclonal antibodies with unique
    mechanism of actions have been approved over the
    past few years, which work on immune checkpoints
    such as CTLA-4, PD-1, and PD-L1.

Figure No.1 Global Monoclonal Antibody
Therapeutics Market Share, By Region (), 2018 -
  • Ongoing research and development of monoclonal
    antibodies for various diseases is expected to
    boost growth of the global monoclonal antibody
    therapeutics market
  • Introduction and supposed success of monoclonal
    antibodies and other biological products has
    spurred the interest of manufacturers in these
    therapies. Success of popular monoclonal
    antibodies such as Avastin, Herceptin, and
    Rituxan (revenues as US 6.8 Bn, US 7.1 Bn, and
    US 5.9 Bn respectively in 2017 globally) has
    spurred manufacturers interest in these
    therapies. Leading manufacturers have resorted to
    boosting pipeline through various ways such as
    merger and acquisitions, partnerships, and
    collaboration. In 2016, AbbVie acquired
    Stemcentrx thereby adding rovalpituzumab tesirine
    (Rova-T) to its product portfolio in oncology
    segment. Cancer treatment (various types) is at
    the forefront of the monoclonal antibody research
    as leading manufacturers are focused on
    development of these drugs for cancer treatment.
    For instance, manufacturers such as Amgen, Inc.
    (e.g. Tezepelumab and others) and Novartis
    International AG (e.g. Ofatumumab and others)
    have several monoclonal antibody programs in the

Market Restraints
  • However, high costs of these products is a major
    concern (in regions with underdeveloped
    reimbursement facilities) in the healthcare
    system and to address this problem, manufacturers
    have resorted to biosimilar products. Biosimilars
    cost much lower than the original products as the
    cost of development is relatively low. Majority
    of the available monoclonal antibody therapeutics
    (cancer treatments) are expected to lose patent
    protection by 2020 and some by 2025. For
    instance, drugs such as Herceptin and Avastin are
    expected to lose patent protection in 2019. These
    factors are expected to restrain the global
    monoclonal antibody therapeutics market growth
    over the forecast period.

Key Players
  • Some of the major players operating in the global
    monoclonal antibody therapeutics market include,
    Pfizer, Inc., Novartis International AG, Amgen,
    Inc., Sanofi S.A., Merck Co., Inc.,
    GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd.,
    AbbVie, Inc., Eily, Lilly, and Company, and
    Bristol-Myers Squibb Company.

  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Reference https//

About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
  • Phone 1-206-701-6702
  • Email

  • Thank You!
  • Kindly follow CMI Social Media Profiles
    for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//